Dual-isotope-based source apportionment of nitrate in 30 rivers draining into the Bohai Sea, north China

Excessive nitrate (NO₃^-) in rivers can lead to water quality deterioration, and can also be directly input into estuaries and oceans, thus posing a serious threat to the stability of their ecosystems. In this study, the concentration, isotopes and sources of NO₃^- in 30 rivers discharging into the Bohai Sea were comprehensively investigated. The mean concentration of NO₃^--N was 2.24 ± 2.11 mg L^-1, with obvious seasonal and spatial variations. In total, 104.24 kt of NO₃^--N was discharged into the Bohai Sea annually, to which the Yellow River Basin and Liao River Basin made the largest contributions. The range of δ¹⁵N-NO₃^- was -1.1‰ to +33.2‰ (mean value, +11.4 ± 5.0‰), with no significant seasonal or spatial differences; the mean value of δ¹⁸O-NO₃^- was +9.4 ± 7.2‰, with much higher values seen in June. Based on the MixSIAR model, manure (24.3 ± 7.5%) and sewage (19.1 ± 14.5%) were the primary sources of NO₃^- in the 30 rivers, followed by NO₃^- fertilizers (16.3 ± 12.5%), soil N (15.5 ± 11.9%), atmospheric deposition of NO₃^- (13.5 ± 5.7%) and NH₄⁺ fertilizers (11.4 ± 8.9%). This finding highlights the vital roles of sewage and manure management in riverine NO₃^-. Using a mathematical method, the contributions of various sources to each river were simulated. The results indicated that management of the Yellow River, Daliao River, Liao River, and Xiaoqing River is more urgently needed than that of other rivers to control Bohai NO₃^- pollution. We believe that this finding will provide guidance for scientific management of NO₃^- pollution in these 30 rivers and the Bohai Sea.

Imaging of inflammatory cellular protagonists in human atherosclerosis: a dual-isotope SPECT approach

Purpose

Atherosclerotic plaque development and progression signifies a complex inflammatory disease mediated by a multitude of proinflammatory leukocyte subsets. Using single photon emission computed tomography (SPECT) coupled with computed tomography (CT), this study tested a new dual-isotope acquisition protocol to assess each radiotracer’s capability to identify plaque phenotype and inflammation levels pertaining to leukocytes expressing leukocyte function-associated antigen-1 (LFA-1) and the leukocyte subset of proinflammatory macrophages expressing somatostatin receptor subtype-2 (SST₂). Individual radiotracer uptake was quantified and the presence of corresponding immunohistological cell markers was assessed.

Methods

Human symptomatic carotid plaque segments were obtained from endarterectomy. Segments were incubated in dual-isotope radiotracers [¹¹¹In]In-DOTA-butylamino-NorBIRT ([¹¹¹In]In-Danbirt) and [^99mTc]Tc-[N^0–1₄,Asp⁰,Tyr³]-octreotate ([^99mTc]Tc-Demotate 2) before scanning with SPECT/CT. Plaque phenotype was classified as pathological intimal thickening, fibrous cap atheroma or fibrocalcific using histology sections based on distinct morphological characteristics. Plaque segments were subsequently immuno-stained with LFA-1 and SST₂ and quantified in terms of positive area fraction and compared against the corresponding SPECT images.

Results

Focal uptake of co-localising dual-radiotracers identified the heterogeneous distribution of inflamed regions in the plaques which co-localised with positive immuno-stained regions of LFA-1 and SST₂. [¹¹¹In]In-Danbirt and [^99mTc]Tc-Demotate 2 uptake demonstrated a significant positive correlation (r = 0.651; p = 0.001). Fibrous cap atheroma plaque phenotype correlated with the highest [¹¹¹In]In-Danbirt and [^99mTc]Tc-Demotate 2 uptake compared with fibrocalcific plaques and pathological intimal thickening phenotypes, in line with the immunohistological analyses.

Conclusion

A dual-isotope acquisition protocol permits the imaging of multiple leukocyte subsets and the pro-inflammatory macrophages simultaneously in atherosclerotic plaque tissue. [¹¹¹In]In-Danbirt may have added value for assessing the total inflammation levels in atherosclerotic plaques in addition to classifying plaque phenotype.

Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours

While radiolabelled antibodies have found great utility as PET and SPECT imaging agents in oncological investigations, a notable shortcoming of these agents is their propensity to accumulate non-specifically within tumour tissue. The degree of this non-specific contribution to overall tumour uptake is highly variable and can ultimately lead to false conclusions. Therefore, in an effort to obtain a reliable measure of inter-individual differences in non-specific tumour uptake of radiolabelled antibodies, we demonstrate that the use of dual-isotope imaging overcomes this issue, enables true quantification of epitope expression levels, and allows non-invasive in vivo immunohistochemistry. The approach involves co-administration of (i) an antigen-targeting antibody labelled with zirconium-89 (89Zr), and (ii) an isotype-matched non-specific control IgG antibody labelled with indium-111 (111In). As an example, the anti-HER2 antibody trastuzumab was radiolabelled with 89Zr, and co-administered intravenously together with its 111In-labelled non-specific counterpart to mice bearing human breast cancer xenografts with differing HER2 expression levels (MDA-MB-468 [HER2-negative], MDA-MB-231 [low-HER2], MDA-MB-231/H2N [medium-HER2], and SKBR3 [high-HER2]). Simultaneous PET/SPECT imaging using a MILabs Vector4 small animal scanner revealed stark differences in the intratumoural distribution of [89Zr]Zr-trastuzumab and [111In]In-IgG, highlighting regions of HER2-mediated uptake and non-specific uptake, respectively. Normalisation of the tumour uptake values and tumour-to-blood ratios obtained with [89Zr]Zr-trastuzumab against those obtained with [111In]In-IgG yielded values which were most strongly correlated (R = 0.94; P = 0.02) with HER2 expression levels for each breast cancer type determined by Western blot and in vitro saturation binding assays, but not non-normalised uptake values. Normalised intratumoural distribution of [89Zr]Zr-trastuzumab correlated well with intratumoural heterogeneity HER2 expression.